MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2026-27)
- Udyam number
- UDYAM-GJ-01-0109163
Market Cap
₹5.72 Cr
VIVANZA · BSE
Share Price
₹1.56
+9.09% today
Revenue
₹116 Cr
FY 2025-26 · +1462.1% YoY
EBITDA
₹0.74 Cr
Margin 0.6%
Net Profit
₹0.40 Cr
FY 2025-26 · +158.8% YoY
P/E (TTM)
14.1x
P/B 1.5x
ROE
9.4%
ROCE 6.0%
Debt / Equity
2.26
Interest cover 38.9x
About Vivanza Biosciences Limited
Data last updated:
Vivanza Biosciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 06 March 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24105GJ1982PLC005057. Its GSTIN is 24AAACI5729B1Z0 (Gujarat). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 530057.
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹4 Cr. It was formerly known as Ivee Injectaa Private Limited and Ivee Injectaa Limited. It is led by directors including Jayendra Mehta (Managing Director) and Rina Kumari.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 403 Sarthik 2 Opp. Rajpath Club S. G. Highway, Ahmedabad, Gujarat, India – 380054.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹115.91 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹40 Lakh (net margin 0.3%) and EBITDA of ₹74 Lakh (EBITDA margin 0.6%). The net worth stands at ₹4.36 Cr (up 10.1% YoY). Total assets are valued at ₹14.55 Cr (up 15.3% YoY).
The company is associated with 1 brand: Vivanza Biosciences. As per MCA filings, the company has open charges of ₹3 Cr on record. Court records list 16 cases involving the company, including 9 filed by the company and 7 filed against it; 1 case is pending. The company has 34 deals on record (34 market trades); the latest was in May 2025. Its 3 peer companies in the Healthcare industry (Biosciences, Formulations, Medical Consumables), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 2 smaller; the largest is KJD Pharma Private Limited with revenue of ₹7.49 Cr.
Vivanza Biosciences Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0109163). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vivanzabiosciences.com.
Company details
CIN L24105GJ1982PLC005057
Registration Number 005057
Incorporation Date 06 March 1982
ROC Ahmedabad
Listing Status Listed - Listed on BSE (530057)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-01-0109163
Name history
Vivanza Biosciences has undergone 2 name changes throughout its history. The company was previously known as Ivee Injectaa Private Limited, and Ivee Injectaa Limited. The current legal name is Vivanza Biosciences Limited.
| Company Name | Status |
|---|---|
| Vivanza Biosciences Limited | Current |
| Ivee Injectaa Private Limited | Previous |
| Ivee Injectaa Limited | Previous |
CIN history
Vivanza Biosciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24105GJ1982PLC005057, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24105GJ1982PLC005057 | Current |
| L24110GJ1982PLC005057 | Previous |
| U24110GJ1982PTC005057 | Previous |
Recognitions & Rankings of Vivanza Biosciences
Contact details
Vivanza Biosciences Limited's registered office is in Ahmedabad, Gujarat.
- Social Media
- Registered Address403 Sarthik 2 Opp. Rajpath Club S. G. Highway, Ahmedabad, Gujarat, India – 380054
- IndustryPharma, Pharmaceutical Retailers & Distributors
Comprehensive company report
Vivanza Biosciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Vivanza Biosciences operates one associated brand: Vivanza Biosciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products and medical gloves are manufactured in India. | vivanzabiosciences.com |
Business activity
The main business activity of Vivanza Biosciences is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Vivanza Biosciences Limited, buy the company report.
Financials of Vivanza Biosciences Limited
FY 2025-26 filings availableVivanza Biosciences Limited reported revenue of ₹115.91 Cr (up 1462.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹116 Cr
+1462.1% YoY
EBITDA
₹0.74 Cr
+300.0% YoY
Profit After Tax
₹0.40 Cr
+158.8% YoY
Net Worth
₹4.36 Cr
+10.1% YoY
Total Assets
₹14.55 Cr
+15.3% YoY
Total Debt
₹10.19 Cr
+17.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 116 | 7.42 | 27.84 | 17.81 | 10.40 | 9.89 | 9.62 |
| Revenue growth | +1462.1% | -73.4% | +56.3% | +71.3% | +5.2% | +2.8% | - |
| EBITDA | 0.74 | (0.37) | 1.08 | 0.68 | (0.07) | 0.11 | (0.35) |
| EBITDA margin | +0.6% | -5.0% | +3.9% | +3.8% | -0.7% | +1.1% | -3.6% |
| Profit before tax | 0.55 | (0.67) | 0.70 | 0.73 | 0.32 | 0.14 | (0.22) |
| Net profit | 0.40 | (0.68) | 0.55 | 0.61 | 0.32 | 0.09 | (0.22) |
| Net profit margin | +0.4% | -9.2% | +2.0% | +3.4% | +3.1% | +0.9% | -2.3% |
| EPS (₹) | 0.10 | (0.17) | 0.14 | 0.15 | 0.83 | 0.19 | (0.51) |
| Balance sheet | |||||||
| Total assets | 14.55 | 12.62 | 9.81 | 12.09 | 9.00 | 3.52 | 3.47 |
| Net worth | 4.36 | 3.96 | 4.64 | 4.09 | 3.49 | 3.16 | 3.08 |
| Total debt | 10.19 | 8.65 | 5.17 | 8.00 | 5.51 | 0.36 | 0.39 |
| Cash & bank | 0.07 | 0.12 | 0.17 | 0.14 | 0.06 | (3.09) | (2.78) |
| Net working capital | 11.53 | 8.55 | 6.05 | 9.16 | 5.90 | 0.08 | 0.25 |
| Cash flow | |||||||
| Cash from operations | (2.58) | (2.50) | 2.04 | (0.95) | 2.47 | (3.08) | 2.98 |
| Cash from investing | (0.12) | (0.01) | (0.04) | 0.00 | 0.00 | (0.02) | 0.00 |
| Cash from financing | 2.65 | 2.46 | (1.98) | 1.03 | (2.48) | 2.80 | (2.75) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.29 | 6.36 | 45.25 | 55.36 | 8.94 | 0.48 | 1.50 | 3.00 |
| Revenue growth (YoY) | +3.9% | +1225.0% | +2916.7% | +1745.3% | +266.4% | - | - | - |
| Other income | 0.37 | 0.01 | 0.08 | 0.01 | 0.02 | 0.05 | 0.01 | 0.00 |
| EBITDA | (0.08) | (0.24) | 0.21 | 0.61 | 0.15 | (0.96) | 0.12 | 0.11 |
| EBITDA margin | -0.9% | -3.8% | +0.5% | +1.1% | +1.7% | -200.0% | +8.0% | +3.7% |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.11 | 0.07 | 0.09 | 0.05 | 0.08 | 0.08 | 0.09 | 0.09 |
| Profit before tax | 0.17 | (0.31) | 0.20 | 0.57 | 0.09 | (0.99) | 0.04 | 0.02 |
| Tax | 0.04 | 0.15 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Net profit | 0.13 | (0.46) | 0.20 | 0.57 | 0.09 | (1.00) | 0.04 | 0.02 |
| EPS (₹) | 0.04 | (0.11) | 0.05 | 0.14 | 0.02 | (0.25) | 0.01 | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 112 | 2.94 | 14.41 | 14.21 | 9.15 | 9.22 | 9.43 |
| Revenue growth | +3717.4% | -79.6% | +1.4% | +55.3% | -0.8% | -2.2% | - |
| EBITDA | 0.71 | (0.38) | 0.80 | 0.73 | 0.08 | 0.12 | (0.31) |
| EBITDA margin | +0.6% | -12.9% | +5.6% | +5.1% | +0.9% | +1.3% | -3.3% |
| Profit before tax | 0.52 | (0.71) | 0.42 | 0.69 | 0.47 | 0.14 | (0.22) |
| Net profit | 0.38 | (0.71) | 0.31 | 0.57 | 0.47 | 0.09 | (0.22) |
| Net profit margin | +0.3% | -24.2% | +2.2% | +4.0% | +5.1% | +1.0% | -2.3% |
| EPS (₹) | 0.09 | (0.17) | 0.08 | 0.14 | 1.16 | 0.25 | (0.51) |
| Balance sheet | |||||||
| Total assets | 11.89 | 10.11 | 7.98 | 10.96 | 8.25 | 3.54 | 3.44 |
| Net worth | 4.40 | 4.02 | 4.72 | 4.40 | 3.83 | 3.37 | 3.27 |
| Total debt | 7.50 | 6.09 | 3.26 | 6.56 | 4.42 | 0.18 | 0.18 |
| Cash & bank | 0.02 | 0.05 | 0.09 | 0.10 | 0.02 | (3.11) | (2.81) |
| Net working capital | 9.27 | 7.59 | 5.44 | 8.44 | 5.74 | 1.03 | 0.94 |
| Cash flow | |||||||
| Cash from operations | (1.21) | (2.47) | 1.80 | 0.16 | (0.68) | (3.08) | 2.80 |
| Cash from investing | (0.12) | (0.01) | (0.04) | 0.00 | 0.00 | (0.02) | 0.00 |
| Cash from financing | 1.31 | 2.44 | (1.77) | (0.08) | 0.65 | 2.80 | (2.58) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.14 | 5.75 | 44.93 | 53.73 | 7.82 | 0.17 | 0.76 | 1.58 |
| Revenue growth (YoY) | +16.9% | +3282.4% | +5811.8% | +3300.6% | +1718.6% | - | - | - |
| Other income | 0.37 | 0.01 | 0.08 | 0.01 | 0.02 | 0.02 | 0.01 | 0.00 |
| Total expenses | 9.22 | 5.80 | 44.76 | 53.23 | 7.74 | 1.07 | 0.64 | 1.48 |
| EBITDA | (0.08) | (0.05) | 0.17 | 0.50 | 0.08 | (0.90) | 0.12 | 0.10 |
| EBITDA margin | -0.9% | -0.9% | +0.4% | +0.9% | +1.0% | -529.4% | +15.8% | +6.3% |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.11 | 0.07 | 0.09 | 0.05 | 0.08 | 0.08 | 0.09 | 0.09 |
| Profit before tax | 0.17 | (0.12) | 0.16 | 0.46 | 0.02 | (0.96) | 0.04 | 0.01 |
| Tax | 0.04 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.29 | 6.36 | 45.25 | 55.36 | 8.94 | 0.48 | 1.50 | 3.00 |
| Revenue growth (YoY) | +3.9% | +1225.0% | +2916.7% | +1745.3% | +266.4% | - | - | - |
| Other income | 0.37 | 0.01 | 0.08 | 0.01 | 0.02 | 0.05 | 0.01 | 0.00 |
| EBITDA | (0.08) | (0.24) | 0.21 | 0.61 | 0.15 | (0.96) | 0.12 | 0.11 |
| EBITDA margin | -0.9% | -3.8% | +0.5% | +1.1% | +1.7% | -200.0% | +8.0% | +3.7% |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.11 | 0.07 | 0.09 | 0.05 | 0.08 | 0.08 | 0.09 | 0.09 |
| Profit before tax | 0.17 | (0.31) | 0.20 | 0.57 | 0.09 | (0.99) | 0.04 | 0.02 |
| Tax | 0.04 | 0.15 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Net profit | 0.13 | (0.46) | 0.20 | 0.57 | 0.09 | (1.00) | 0.04 | 0.02 |
| EPS (₹) | 0.04 | (0.11) | 0.05 | 0.14 | 0.02 | (0.25) | 0.01 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 116 | 7.42 | 27.84 | 17.81 | 10.40 | 9.89 | 9.62 |
| Revenue growth | +1462.1% | -73.4% | +56.3% | +71.3% | +5.2% | +2.8% | - |
| Other income | 0.11 | 0.06 | 0.05 | 0.48 | 0.83 | 0.51 | 0.57 |
| Total expenses | 115 | 7.79 | 26.76 | 17.13 | 10.47 | 9.78 | 9.97 |
| Employee cost | 0.49 | 0.58 | 0.45 | 0.31 | 0.25 | 0.34 | 0.30 |
| EBITDA | 0.74 | (0.37) | 1.08 | 0.68 | (0.07) | 0.11 | (0.35) |
| EBITDA margin | +0.6% | -5.0% | +3.9% | +3.8% | -0.7% | +1.1% | -3.6% |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest | 0.28 | 0.35 | 0.42 | 0.43 | 0.43 | 0.47 | 0.44 |
| Profit before tax | 0.55 | (0.67) | 0.70 | 0.73 | 0.32 | 0.14 | (0.22) |
| Tax | 0.15 | 0.01 | 0.15 | 0.12 | 0.00 | 0.05 | 0.00 |
| Net profit | 0.40 | (0.68) | 0.55 | 0.61 | 0.32 | 0.09 | (0.22) |
| Net profit margin | +0.4% | -9.2% | +2.0% | +3.4% | +3.1% | +0.9% | -2.3% |
| EPS (₹) | 0.10 | (0.17) | 0.14 | 0.15 | 0.83 | 0.19 | (0.51) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Reserves & surplus | 0.36 | (0.04) | 0.64 | 0.09 | (0.51) | (0.84) | (0.92) |
| Shareholders' funds (net worth) | 4.36 | 3.96 | 4.64 | 4.09 | 3.49 | 3.16 | 3.08 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 10.09 | 8.65 | 5.17 | 8.00 | 5.51 | 0.36 | 0.39 |
| Total debt | 10.19 | 8.65 | 5.17 | 8.00 | 5.51 | 0.36 | 0.39 |
| Total liabilities | 14.55 | 12.62 | 9.81 | 12.09 | 9.00 | 3.52 | 3.47 |
| Assets | |||||||
| Gross block | 2.69 | 2.57 | 2.56 | 2.52 | 2.52 | 2.52 | 2.50 |
| Net block | 2.44 | 2.34 | 2.34 | 2.31 | 2.32 | 2.32 | 2.31 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 3.55 | 2.26 | 2.01 | 2.47 | 2.43 | 0.65 | 0.97 |
| Sundry debtors | 12.38 | 8.06 | 11.54 | 12.48 | 7.84 | 6.25 | 6.54 |
| Cash & bank balances | 0.07 | 0.12 | 0.17 | 0.14 | 0.06 | (3.09) | (2.78) |
| Loans & advances | 3.06 | 1.95 | 2.03 | 4.46 | 2.13 | 1.20 | 4.41 |
| Total current assets | 19.06 | 12.39 | 15.75 | 19.55 | 12.46 | 5.01 | 9.14 |
| Total current liabilities | 7.53 | 3.84 | 9.70 | 10.39 | 6.56 | 4.93 | 8.89 |
| Net working capital | 11.53 | 8.55 | 6.05 | 9.16 | 5.90 | 0.08 | 0.25 |
| Total assets | 14.55 | 12.62 | 9.81 | 12.09 | 9.00 | 3.52 | 3.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.12 | 0.17 | 0.14 | 0.06 | 0.07 | (2.81) | (3.00) |
| Net cash from operating activities | (2.58) | (2.50) | 2.04 | (0.95) | 2.47 | (3.08) | 2.98 |
| Net cash from investing activities | (0.12) | (0.01) | (0.04) | 0.00 | 0.00 | (0.02) | 0.00 |
| Net cash from financing activities | 2.65 | 2.46 | (1.98) | 1.03 | (2.48) | 2.80 | (2.75) |
| Net change in cash | (0.05) | (0.05) | 0.03 | 0.09 | (0.01) | (0.30) | 0.22 |
| Closing cash | 0.07 | 0.12 | 0.17 | 0.14 | 0.06 | (3.09) | (2.78) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1462.1% | -73.4% | +56.3% | +71.3% | +5.2% | +2.8% | - |
| EBITDA growth | +300.0% | -134.3% | +58.8% | +1071.4% | -163.6% | +131.4% | - |
| PBT growth | +9998.0% | - | -4.1% | +128.1% | +128.6% | +9998.0% | +48.8% |
| Net income growth | +158.8% | -223.6% | -9.8% | +90.6% | +255.6% | +140.9% | - |
| Revenue CAGR (3Y) | +86.7% | -10.6% | +41.2% | +22.8% | +57.5% | +15.4% | +40.5% |
| EBITDA CAGR (3Y) | +2.9% | +74.2% | +114.1% | - | +91.3% | -43.5% | +3.0% |
| Profitability & leverage | |||||||
| Net income margin | +0.4% | -9.2% | +2.0% | +3.4% | +3.1% | +0.9% | -2.3% |
| Return on capital employed | +6.0% | 0.0% | +10.2% | +10.7% | +11.0% | +15.3% | 0.0% |
| Return on net worth | +9.4% | 0.0% | +12.6% | +14.8% | +8.3% | +2.3% | 0.0% |
| Debt / equity | 2.26 | 1.61 | 1.51 | 1.78 | 0.88 | 0.12 | 0.29 |
| Long-term debt / equity | 0.51 | 0.70 | 0.47 | 0.53 | 0.39 | 0.03 | 0.12 |
| Interest cover | 38.89 | -92.11 | 39.25 | 63.24 | -537.50 | 470.00 | -125.71 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 44.07 | 2.89 | 10.96 | 7.07 | 4.13 | 3.94 | 3.85 |
| Inventory turnover | 39.90 | 3.48 | 12.43 | 7.27 | 6.75 | 12.21 | 6.48 |
| Debtors turnover | 11.34 | 0.76 | 2.32 | 1.75 | 1.48 | 1.55 | 1.57 |
| EPS (₹) | 0.10 | (0.17) | 0.14 | 0.15 | 0.83 | 0.19 | (0.51) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.09 | 0.99 | 1.16 | 1.02 | 8.73 | 7.90 | 7.71 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.14 | 5.75 | 44.93 | 53.73 | 7.82 | 0.17 | 0.76 | 1.58 |
| Revenue growth (YoY) | +16.9% | +3282.4% | +5811.8% | +3300.6% | +1718.6% | - | - | - |
| Other income | 0.37 | 0.01 | 0.08 | 0.01 | 0.02 | 0.02 | 0.01 | 0.00 |
| Total expenses | 9.22 | 5.80 | 44.76 | 53.23 | 7.74 | 1.07 | 0.64 | 1.48 |
| EBITDA | (0.08) | (0.05) | 0.17 | 0.50 | 0.08 | (0.90) | 0.12 | 0.10 |
| EBITDA margin | -0.9% | -0.9% | +0.4% | +0.9% | +1.0% | -529.4% | +15.8% | +6.3% |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.11 | 0.07 | 0.09 | 0.05 | 0.08 | 0.08 | 0.09 | 0.09 |
| Profit before tax | 0.17 | (0.12) | 0.16 | 0.46 | 0.02 | (0.96) | 0.04 | 0.01 |
| Tax | 0.04 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 112 | 2.94 | 14.41 | 14.21 | 9.15 | 9.22 | 9.43 |
| Revenue growth | +3717.4% | -79.6% | +1.4% | +55.3% | -0.8% | -2.2% | - |
| Other income | 0.11 | 0.03 | 0.05 | 0.39 | 0.83 | 0.50 | 0.53 |
| Total expenses | 112 | 3.32 | 13.61 | 13.48 | 9.07 | 9.10 | 9.74 |
| Employee cost | 0.33 | 0.37 | 0.31 | 0.22 | 0.08 | 0.11 | 0.10 |
| EBITDA | 0.71 | (0.38) | 0.80 | 0.73 | 0.08 | 0.12 | (0.31) |
| EBITDA margin | +0.6% | -12.9% | +5.6% | +5.1% | +0.9% | +1.3% | -3.3% |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest | 0.28 | 0.35 | 0.42 | 0.43 | 0.43 | 0.47 | 0.44 |
| Profit before tax | 0.52 | (0.71) | 0.42 | 0.69 | 0.47 | 0.14 | (0.22) |
| Tax | 0.14 | 0.00 | 0.11 | 0.12 | 0.00 | 0.05 | 0.00 |
| Net profit | 0.38 | (0.71) | 0.31 | 0.57 | 0.47 | 0.09 | (0.22) |
| Net profit margin | +0.3% | -24.2% | +2.2% | +4.0% | +5.1% | +1.0% | -2.3% |
| EPS (₹) | 0.09 | (0.17) | 0.08 | 0.14 | 1.16 | 0.25 | (0.51) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Reserves & surplus | 0.40 | 0.02 | 0.72 | 0.40 | (0.17) | (0.63) | (0.73) |
| Shareholders' funds (net worth) | 4.40 | 4.02 | 4.72 | 4.40 | 3.83 | 3.37 | 3.27 |
| Secured loans | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 7.40 | 6.09 | 3.26 | 6.56 | 4.42 | 0.18 | 0.18 |
| Total debt | 7.50 | 6.09 | 3.26 | 6.56 | 4.42 | 0.18 | 0.18 |
| Total liabilities | 11.89 | 10.11 | 7.98 | 10.96 | 8.25 | 3.54 | 3.44 |
| Assets | |||||||
| Gross block | 0.19 | 0.07 | 0.06 | 0.02 | 0.02 | 0.02 | 0.00 |
| Net block | 0.12 | 0.02 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 |
| Inventories | 2.95 | 1.84 | 1.80 | 1.61 | 2.23 | 0.40 | 0.85 |
| Sundry debtors | 10.66 | 7.39 | 10.37 | 12.18 | 7.35 | 6.11 | 6.41 |
| Cash & bank balances | 0.02 | 0.05 | 0.09 | 0.10 | 0.02 | (3.11) | (2.81) |
| Loans & advances | 1.97 | 2.11 | 2.08 | 4.03 | 2.10 | 2.02 | 5.32 |
| Total current assets | 15.60 | 11.39 | 14.34 | 17.92 | 11.70 | 5.42 | 9.77 |
| Total current liabilities | 6.33 | 3.80 | 8.90 | 9.48 | 5.96 | 4.39 | 8.83 |
| Net working capital | 9.27 | 7.59 | 5.44 | 8.44 | 5.74 | 1.03 | 0.94 |
| Total assets | 11.89 | 10.11 | 7.98 | 10.96 | 8.25 | 3.54 | 3.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 0.09 | 0.10 | 0.02 | 0.05 | (2.81) | (3.03) |
| Net cash from operating activities | (1.21) | (2.47) | 1.80 | 0.16 | (0.68) | (3.08) | 2.80 |
| Net cash from investing activities | (0.12) | (0.01) | (0.04) | 0.00 | 0.00 | (0.02) | 0.00 |
| Net cash from financing activities | 1.31 | 2.44 | (1.77) | (0.08) | 0.65 | 2.80 | (2.58) |
| Net change in cash | (0.03) | (0.04) | (0.01) | 0.09 | (0.03) | (0.30) | 0.22 |
| Closing cash | 0.02 | 0.05 | 0.09 | 0.10 | 0.02 | (3.11) | (2.81) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3717.4% | -79.6% | +1.4% | +55.3% | -0.8% | -2.2% | - |
| EBITDA growth | +286.8% | -147.5% | +9.6% | +812.5% | -33.3% | +138.7% | - |
| PBT growth | +9998.0% | - | -39.1% | +46.8% | +235.7% | +9998.0% | +51.1% |
| Net income growth | +153.5% | -329.0% | -45.6% | +21.3% | +422.2% | +140.9% | - |
| Revenue CAGR (3Y) | +99.2% | -31.5% | +16.1% | +14.7% | +60.3% | +12.7% | +39.6% |
| EBITDA CAGR (3Y) | -0.9% | - | +88.2% | - | - | -42.8% | +24.7% |
| Profitability & leverage | |||||||
| Net income margin | +0.3% | -24.2% | +2.2% | +4.0% | +5.1% | +1.0% | -2.3% |
| Return on capital employed | +7.3% | -3.9% | +9.0% | +11.6% | +14.1% | +16.3% | 0.0% |
| Return on net worth | +9.0% | -16.0% | +7.0% | +13.6% | +11.5% | +2.8% | 0.0% |
| Debt / equity | 1.61 | 1.07 | 1.08 | 1.33 | 0.64 | 0.05 | 0.16 |
| Long-term debt / equity | 0.20 | 0.18 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 40.58 | -89.74 | 53.16 | 58.90 | 614.29 | 427.27 | -141.94 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 863.31 | 45.23 | 360.25 | 710.50 | 457.50 | 922.00 | 0.00 |
| Inventory turnover | 46.86 | 1.62 | 8.45 | 7.40 | 6.96 | 14.75 | 6.83 |
| Debtors turnover | 12.44 | 0.33 | 1.28 | 1.46 | 1.36 | 1.47 | 1.58 |
| EPS (₹) | 0.09 | (0.17) | 0.08 | 0.14 | 1.16 | 0.25 | (0.51) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.10 | 1.01 | 1.18 | 1.10 | 9.57 | 8.41 | 8.16 |
To see the full year-wise statements and ratios of Vivanza Biosciences Limited, buy the company report.
Board of directors of Vivanza Biosciences Limited
Vivanza Biosciences has 4 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rina Kumari | Director | 30 Apr 2024 | 2 Years 5 Months | Current |
| Jayendra Mehta Also directs: Vitaaglobal Bioscience Private Limited, Vaishali Lifecare Private Limited, Vital Intelligence Technology Private Limited and 1 more | Managing Director | 25 Apr 2023 | 3 Years 6 Months | Current |
| Sarang Bharat Pathak | Director | 30 Aug 2025 | 1 Years 1 Months | Current |
| Hitesh Pradeep Rijwani | Director | 12 May 2025 | 1 Years 5 Months | Current |
Peer comparison
Vivanza Biosciences Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Biosciences, Formulations, Medical Consumables), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vivanza Biosciences Limitedthis company | ₹115.91 Cr (FY 2026) | ₹40 Lakh | 0.3% | 1462.1% | Ahmedabad, Gujarat, India | |
| KJD Pharma Private Limited | ₹7.49 Cr (FY 2025) | Bidar, Karnataka, India | ||||
| JMS Medicon Private Limited | ₹7.46 Cr (FY 2024) | 20.0% | New Delhi, Delhi, India | |||
| Karak Pharmaceuticals Private Limited | ₹7.46 Cr (FY 2024) | 9.0% | Midnapore, West Bengal, India |
To see the full peer comparison of Vivanza Biosciences Limited, buy the company report.
Charges & borrowings
Open charges
₹3 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 10 Jan 2017 | 100072526 | State Bank of India | ₹3 Cr | Open |
Total charge records: 1 View all charges
Deals & funding
Vivanza Biosciences Limited has 34 deals on record (34 market trades); the latest was in May 2025.
Total deals
34
Market trades
34
Deals on record (5 of 34)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2024 | Market trade | ₹13.7 Lakh | Buyer: an individual Seller: Anant Wealth Consultants Private Limited , an individual |
| Dec 2024 | Market trade | ₹35.1 Lakh | Buyer: Anant Wealth Consultants Private Limited , an individual Seller: Vishal Chinubhai Suthar Huf, an individual |
| Nov 2024 | Market trade | ₹18.6 Lakh | Seller: Ashoka Metcast Limited , an individual |
| Oct 2024 | Market trade | ₹24 Lakh | Buyer: an individual Seller: Ashoka Metcast Limited , an individual |
| Aug 2024 | Market trade | ₹8.8 Lakh | Seller: Ashoka Metcast Limited |
To see the full deal history of Vivanza Biosciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Vivanza Biosciences Limited has 16 court cases on record: 9 filed by Vivanza Biosciences, 7 filed against it. 1 case is pending and 15 are disposed.
Total cases
16
Filed by the company
9
Filed against the company
7
Pending
1
Disposed
15
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 11 | 2 | 0 |
| District courts | 5 | 5 | 1 |
Cases on record (5 of 16)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Jabalpur, Madhya Pradesh | Court case (MJC SUC) | Filed against the company | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by an individual | Disposed |
| High Court, GUJARAT | Court case (COMP) | Filed by the company against an individual | Disposed |
| High Court, GUJARAT | Commercial suit | Filed by the company against an individual | Disposed |
| High Court, GUJARAT | Court case (COMP) | Filed by the company | Disposed |
To see the full case history of Vivanza Biosciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Vivanza Biosciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Vivanza Biosciences has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACI5729B1Z0 | Gujarat | Active | 01 Jul 2017 |
| 07AAACI5729B1ZW | Delhi | Active | 07 Dec 2021 |
To see the full GST registrations and return filing status of Vivanza Biosciences Limited, buy the company report.
Recent activity
Vivanza Biosciences Limited has 27 board changes on record since 2012: 6 appointments and 21 cessations. The latest: Hitesh Pradeep Rijwani ceased to be Additional Director on 24 Sep 2025.
Filing
Vivanza Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Vivanza Biosciences Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Ceased
Hitesh Pradeep Rijwani ceased to be Additional Director.
Ceased
Sarang Bharat Pathak ceased to be Additional Director.
Appointed
Sarang Bharat Pathak was appointed as Director.
Appointed
Hitesh Pradeep Rijwani was appointed as Director.
Ceased
Aagam Pankajbhai Shah ceased to be Additional Director.
Ceased
Rina Kumari ceased to be Additional Director.
Appointed
Rina Kumari was appointed as Director.
Ceased
Apeksha Sanjaykumar Vyas ceased to be Additional Director.
Appointed
Jayendra Mehta was appointed as Managing Director.
Ceased
Aesha Jashwantray Mashru ceased to be Company Secretary.
19 earlier events are in the company report.
News
Frequently asked questions
Vivanza Biosciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 06 March 1982 (44+ years old) and is registered under CIN L24105GJ1982PLC005057. Listed on BSE: 530057.
Vivanza Biosciences reported revenue of ₹115.91 Cr for FY 2025-26 (up 1462.1% YoY) based on consolidated financials.
Vivanza Biosciences has 4 current directors:
- Jayendra Mehta - Managing Director
- Rina Kumari - Director
- Sarang Bharat Pathak - Director
- Hitesh Pradeep Rijwani - Director
The latest financial statements of Vivanza Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Vivanza Biosciences is 24AAACI5729B1Z0, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 07AAACI5729B1ZW (Delhi).
The CIN (Corporate Identification Number) of Vivanza Biosciences is L24105GJ1982PLC005057. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vivanza Biosciences is a listed company as per MCA records. Its shares are listed on BSE (code: 530057).
Vivanza Biosciences has 16 court cases on record: 9 filed by the company and 7 filed against it. 1 is pending. Most are in the high courts.
Vivanza Biosciences was incorporated on 06 March 1982, making it 44+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Vivanza Biosciences has 34 deals on record (34 market trades); the latest was in May 2025.
The peers of Vivanza Biosciences by revenue are KJD Pharma Private Limited, JMS Medicon Private Limited, Karak Pharmaceuticals Private Limited, all in the Healthcare industry (Biosciences, Formulations, Medical Consumables), with the same principal business activity (wholesale trading).